Portal de Periódicos da CAPES

Haemodynamic effects of sacubitril/valsartan in advanced heart failure

2022; Wiley; Volume: 9; Issue: 2 Linguagem: Inglês

10.1002/ehf2.13755

2055-5822

Piero Gentile, Rosaria Cantone, Enrico Perna, Enrico Ammirati, Marisa Varrenti, Luciana D’Angelo, Alessandro Verde, Grazia Foti, Gabriella Masciocco, Andrea Garascia, Maria Frigerio, Manlio Cipriani,

Cardiac pacing and defibrillation studies

The angiotensin receptor-neprilysin inhibitor (ARNI), sacubitril/valsartan, has been shown to be effective in treatment of patients with heart failure (HF), but limited data are available in patients with advanced disease. This retrospective observational study assessed the effects of ARNI treatment in patients with advanced HF.